Table 2.
Patient Characteristics Serum Samples and Western Blot Biopsies
| Serum/Plasma | Western Blot Analysis | ||
|---|---|---|---|
| Total number of patients included | 33 | 9 | |
| Non-IBD | 17 (51.5) | 5 (55.6) | |
| UC remission | 16 (48.5) | 4 (44.4) | |
| Female/male | |||
| Non-IBD | 9 (52.9)/8 (47.1) | 3 (60.0)/2 (40) | |
| UC remission | 7 (43.8)/9 (56.3) | 1 (25)/3 (75) | |
| Age (unknown), y | |||
| Non-IBD | 30.3 ± 9.7 | 49.8 ± 24.2 | |
| UC remission | 43.8 ± 7.7 (10) | 60.15 ± 17.04 | |
| Origin of biopsy | Not applicable | Non-IBD | UC |
|---|---|---|---|
| Cecum | — | 1 (25.0) | |
| Colon ascendens | 1 (20.0) | 1 (25.0) | |
| Flexura hepatica | 1 (20.0) | — | |
| Colon descendens | 1 (20.0) | 1 (25.0) | |
| Colon sigmoideum | 1 (20.0) | — | |
| Rectum | 1 (20.0) | 1 (25.0) |
| Medication | UC | UC | |
|---|---|---|---|
| Mesalazine/mesalazine klysmen | 15 (93.8) | 2 (50) | |
| TNF-α inhibitors | 8 (50.0) | — | |
| Prednisone | 1 (6.3) | 2 (50) | |
| Vedolizumab | 3 (18.8) | — | |
| Budesonide klysmen | 2 (12.5) | — | |
| Thiopurines | 2 (12.5) | — | |
| Hydrocortisone rectal foam | — | 1 (25) | |
| Ciprofloxacin | — | 1 (25) | |
| Sulfasalazine | — | 1 (25) | |
| Tacrolimus | — | 1 (25) | |
NOTE. Values are n (%) or mean ± SD, unless otherwise indicated.
IBD, inflammatory bowel disease; TNF-α, tumor necrosis factor α; UC, ulcerative colitis.